Laurent Laforest1, Nicolas Roche2, Gilles Devouassoux3, Manon Belhassen1, Christos Chouaid4, Marine Ginoux1, Eric Van Ganse5. 1. HESPER 7425, Health Services and Performance Research, Université Claude Bernard Lyon, France; PELyon, PharmacoEpidemiologie Lyon, Lyon, France. 2. Respiratory and Intensive Care Medicine, Cochin Hospital Group, Paris Descartes University (EA2511), Paris, France. 3. Respiratory Medicine, Croix-Rousse University Hospital, Lyon, France. 4. Respiratory Medicine, Creteil University Hospital, Creteil, France. 5. HESPER 7425, Health Services and Performance Research, Université Claude Bernard Lyon, France; PELyon, PharmacoEpidemiologie Lyon, Lyon, France; Respiratory Medicine, Croix-Rousse University Hospital, Lyon, France. Electronic address: eric.van-ganse@univ-lyon1.fr.
Abstract
BACKGROUND: In chronic obstructive pulmonary disease (COPD), the role of specific comorbidities on all-cause mortality is of major interest particularly with a database representative of the beneficiaries covered by the French health system. We investigated the frequency and the role of major comorbidities on all-cause mortality in a population-based cohort of COPD patients, and whether this impact was modulated by gender. METHODS: A historical cohort was identified in the French claims data. Patients aged ≥45 years were selected in 2006 from the French national claims data (1/97(th) random sample) by at least one of the following criteria: (a) COPD-related hospitalisations, (b) long-term disease status for COPD, (c) dispensations of bronchodilators. Cardiovascular diseases, diabetes, depression and cancer were defined by specific therapy and/or long-term disease status. The impact of comorbidities on mortality was investigated during a seven-year follow-up period (2007-2013), using Cox models. RESULTS: In 4,237 patients (mean age 68 years, 55% males, mean annual death-rate 4.9%), cardiovascular diseases, diabetes, depression and cancers were identified in 68.7%, 15.2%, 14.2% and 10.6% of patients, respectively. Associations with mortality were significant for cardiovascular diseases (HR = 1.2, 95%CI = [1.0-1.4]), diabetes (HR = 1.2, 95%CI = [1.0-1.4]), depression (HR = 1.4, 95%CI = [1.2-1.6]) and cancers (HR = 1.6, 95%CI = [1.4-1.9]), with no difference between genders. CONCLUSIONS: In the French population, major comorbidities are common in COPD, particularly cardiovascular diseases that occur in over two thirds of patients. The impact of comorbidities on mortality was not related to their prevalence, with cancer having the largest impact.
BACKGROUND: In chronic obstructive pulmonary disease (COPD), the role of specific comorbidities on all-cause mortality is of major interest particularly with a database representative of the beneficiaries covered by the French health system. We investigated the frequency and the role of major comorbidities on all-cause mortality in a population-based cohort of COPD patients, and whether this impact was modulated by gender. METHODS: A historical cohort was identified in the French claims data. Patients aged ≥45 years were selected in 2006 from the French national claims data (1/97(th) random sample) by at least one of the following criteria: (a) COPD-related hospitalisations, (b) long-term disease status for COPD, (c) dispensations of bronchodilators. Cardiovascular diseases, diabetes, depression and cancer were defined by specific therapy and/or long-term disease status. The impact of comorbidities on mortality was investigated during a seven-year follow-up period (2007-2013), using Cox models. RESULTS: In 4,237 patients (mean age 68 years, 55% males, mean annual death-rate 4.9%), cardiovascular diseases, diabetes, depression and cancers were identified in 68.7%, 15.2%, 14.2% and 10.6% of patients, respectively. Associations with mortality were significant for cardiovascular diseases (HR = 1.2, 95%CI = [1.0-1.4]), diabetes (HR = 1.2, 95%CI = [1.0-1.4]), depression (HR = 1.4, 95%CI = [1.2-1.6]) and cancers (HR = 1.6, 95%CI = [1.4-1.9]), with no difference between genders. CONCLUSIONS: In the French population, major comorbidities are common in COPD, particularly cardiovascular diseases that occur in over two thirds of patients. The impact of comorbidities on mortality was not related to their prevalence, with cancer having the largest impact.
Authors: Lucas M Donovan; Peter J Rise; Shannon S Carson; Laura C Feemster; Matthew F Griffith; Vishesh K Kapur; Jerry A Krishnan; Peter K Lindenauer; Richard A Mularski; Edward T Naureckas; Brian N Palen; Elizabeth C Parsons; Laura J Spece; Michael V Vitiello; David H Au Journal: Ann Am Thorac Soc Date: 2017-12
Authors: Michael Schivo; Timothy E Albertson; Angela Haczku; Nicholas J Kenyon; Amir A Zeki; Brooks T Kuhn; Samuel Louie; Mark V Avdalovic Journal: J Investig Med Date: 2017-03-03 Impact factor: 2.895
Authors: Catherine A Spilling; Mohani-Preet K Bajaj; Daniel R Burrage; Sachelle Ruickbie; N Jade Thai; Emma H Baker; Paul W Jones; Thomas R Barrick; James W Dodd Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-08-21
Authors: Marc Miravitlles; Nicolas Roche; João Cardoso; David Halpin; Zaurbek Aisanov; Hannu Kankaanranta; Vladimir Kobližek; Paweł Śliwiński; Leif Bjermer; Michael Tamm; Francesco Blasi; Claus F Vogelmeier Journal: Respir Res Date: 2018-01-18
Authors: Youngmok Park; Ji Ye Jung; Young Sam Kim; Kyung Soo Chung; Joo Han Song; Song Yee Kim; Eun Young Kim; Young Ae Kang; Moo Suk Park; Joon Chang; Ah Young Leem Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-07-18
Authors: Thomas Janssens; Zora Van de Moortel; Wolfgang Geidl; Johannes Carl; Klaus Pfeifer; Nicola Lehbert; Michael Wittmann; Konrad Schultz; Andreas von Leupoldt Journal: J Clin Med Date: 2019-09-13 Impact factor: 4.241